Article Versions Notes

Capdevila O, Mitjavila F, Espinosa G, Caminal-Montero L, Marín-Ballvè A, González León R, Castro A, Canora J, Pinilla B, Fonseca E, et al. Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients. Medicina. 2023; 59(8):1362. https://doi.org/10.3390/medicina59081362

Capdevila, O., F. Mitjavila, G. Espinosa, L. Caminal-Montero, A. Marín-Ballvè, R. González León, A. Castro, J. Canora, B. Pinilla, E. Fonseca, and et al. 2023. "Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients" Medicina 59, no. 8: 1362. https://doi.org/10.3390/medicina59081362

Capdevila, O., Mitjavila, F., Espinosa, G., Caminal-Montero, L., Marín-Ballvè, A., González León, R., Castro, A., Canora, J., Pinilla, B., Fonseca, E., & Ruiz-Irastorza, G., on behalf of RELES, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine. (2023). Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients. Medicina, 59(8), 1362. https://doi.org/10.3390/medicina59081362